Understanding Biological Evaluation Standards for Medical Devices: A Guide for Safer Health Care

Today's medical devices must not only perform as intended but also guarantee the highest levels of safety for both patients and users. The biological evaluation of medical devices, governed by a dedicated series of international standards, forms the backbone of this responsibility. This article explores four pivotal standards—EN ISO 10993-10:2023, EN ISO 10993-1:2025, EN ISO 10993-17:2023, and EN ISO 10993-23:2021—and sheds light on their critical roles in health care. For anyone involved in device manufacturing, regulatory affairs, or quality management, understanding and implementing these standards is now a non-negotiable requirement for market access, business growth, and ensuring human safety.

Overview / Introduction

Medical devices have become increasingly sophisticated and diverse, ranging from everyday disposables like bandages to high-tech implants and diagnostic tools. Whether a device comes into direct or indirect contact with the human body, it can pose potential biological risks including toxicity, irritation, or allergic reactions.

In response to these challenges, the International Organization for Standardization (ISO) and the European Committee for Standardization (CEN) developed the EN ISO 10993 series. These standards mandate rigorous evaluation processes, testing methods, and risk assessments that help ensure biological safety throughout a product's life cycle. Adoption of these medical device standards is now tightly integrated with regulatory requirements, especially under the European Union's Medical Device Regulation (MDR) and other global frameworks.

By the end of this guide, you will understand:

• The scope and significance of the four key standards for biological evaluation
• How they enhance productivity, security, and facilitate scaling in medical device businesses
• Best practices for compliance, with user-friendly explanations for the general public and professionals alike
• Direct access links to full standards for in-depth study and implementation

Detailed Standards Coverage

EN ISO 10993-10:2023 – Tests for Skin Sensitization

Biological evaluation of medical devices – Part 10: Tests for skin sensitization (ISO 10993-10:2021)

This standard governs how medical devices and their components are assessed for their potential to cause skin sensitization—a form of allergic reaction that develops after skin contact with certain chemicals or substances. The document outlines detailed procedures for both in vivo (animal-based) skin sensitization test methods, such as the guinea pig maximization test and the murine local lymph node assay. It also offers guidance for preparing materials and interpreting biological responses.

Key aspects include:

• Precise directions for test sample preparation, choice of animal models, and observation procedures
• Guidance on the interpretation of test results for regulatory submission
• Emphasis on animal welfare and the potential for non-animal testing alternatives

Who should comply: Manufacturers of all medical devices with any skin contact, including those producing gloves, implants, patches, and wound care products.

Practical implications: Implementing this standard protects users from allergic reactions, prevents costly recalls, and streamlines regulatory approvals. With increasing consumer awareness and legal sensitivity to allergies, compliance is also a sound business risk mitigation tool.

Key highlights:

• Includes both in vivo and emerging non-animal test methods
• Offers interpretation criteria aligned with EU regulations
• Facilitates market access under MDR and global requirements

Access the full standard:View EN ISO 10993-10:2023 on iTeh Standards

EN ISO 10993-1:2025 – General Principles for Biological Safety within Risk Management

Biological evaluation of medical devices – Part 1: Requirements and general principles for the evaluation of biological safety within a risk management process (ISO 10993-1:2025)

As the cornerstone of the EN ISO 10993 family, Part 1 defines the overarching framework for biological risk assessment in medical devices. It specifies that biological evaluation must be part of a structured risk management process, in accordance with ISO 14971. The standard applies to any device that has direct or indirect human contact, whether for patients or users.

This standard addresses:

• Assessment of biological risks associated with device constituents and tissue-device interactions
• Considering all potential hazards throughout the device life cycle—from design and production to end-of-use
• The integration of risk management, clinical evaluation, and toxicological testing
• Reference to additional EN ISO 10993 parts for specific risk endpoints (e.g., cytotoxicity, genotoxicity, irritation)

Who should comply: All medical device manufacturers, research and development teams, regulatory affairs professionals, and quality managers.

Practical implications: Adhering to this standard ensures a robust, well-documented process for biological risk reduction. This drives product quality, boosts trust among regulators, accelerates time to market, and creates the foundation for international scaling.

Key highlights:

• Comprehensive risk management for biological safety
• Addresses both patients and non-patient users' exposure
• Supports global regulatory submissions and post-market activities

Access the full standard:View EN ISO 10993-1:2025 on iTeh Standards

EN ISO 10993-17:2023 – Toxicological Risk Assessment of Medical Device Constituents

Biological evaluation of medical devices – Part 17: Toxicological risk assessment of medical device constituents (ISO 10993-17:2023)

This standard lays out a comprehensive process for evaluating and controlling the toxicological risks posed by chemical and material constituents in medical devices. Leveraging chemical characterization data from ISO 10993-18, Part 17 guides users in determining whether exposure to various constituents is within safe, tolerable limits.

Scope includes:

• Detailed steps for hazard identification, risk estimation, and establishing tolerable exposure levels
• Calculation of patient and user exposure doses, application of thresholds like the Threshold of Toxicological Concern (TTC)
• Exclusion criteria for device parts that do not contact the patient and for established equivalent devices

Who should comply: Toxicologists, regulatory affairs specialists, R&D chemists, and device manufacturers, especially those with complex devices or novel materials.

Practical implications: Integrating toxicological risk assessment prevents harmful exposures, enables objective evidence for regulatory submissions, and demonstrates due diligence in protecting public health.

Key highlights:

• Establishes clear methods for risk evaluation of device constituents
• Employs internationally recognized toxicological thresholds
• Mandates reporting and documentation for traceability

Access the full standard:View EN ISO 10993-17:2023 on iTeh Standards

EN ISO 10993-23:2021 – Tests for Irritation

Biological evaluation of medical devices – Part 23: Tests for irritation (ISO 10993-23:2021)

Irritation testing is vital for any product or material coming into repeated or prolonged contact with tissue—whether skin, mucosal, or ocular. This standard defines systematic procedures, including in vitro and in vivo methods, for predicting and classifying the irritation potential of devices or their extracts. It aligns irritation testing with broader risk management frameworks and references ISO 10993-1 and ISO 10993-2 (animal welfare).

Key elements encompass:

• Pre-test considerations, including in silico and in vitro modeling
• Stepwise approaches for dermal, mucous membrane, and ocular irritation
• Clear criteria for test interpretation, reporting, and regulatory alignment

Who should comply: Manufacturers of wound dressings, contact lenses, catheters, and any device with repeat tissue contact.

Practical implications: Compliance is directly linked to device safety, regulatory approval, and liability minimization. With the trend towards animal-free testing, this standard’s inclusion of advanced in vitro alternatives demonstrates environmental responsibility.

Key highlights:

• Integrates modern, animal-free testing methodologies
• Aligns with global regulatory and safety requirements
• Supports faster, more ethical device development

Access the full standard:View EN ISO 10993-23:2021 on iTeh Standards

Industry Impact & Compliance

The biological evaluation standards described above are more than regulatory hurdles—they are strategic assets for any organization in the medical device sector. Their implementation has profound implications for product development, risk management, operational efficiency, and, ultimately, patient safety.

How These Standards Affect Businesses

• Market Access: Compliance with EN ISO 10993 series is mandatory in major global markets including the EU, US, and many others. Non-compliance results in delays, rejections, or costly recalls.
• Reputation and Trust: Devices adhering to these standards are perceived as higher quality, building essential confidence among health care providers, patients, and regulators.
• Liability Mitigation: Demonstrating compliance forms a legal defense in the event of adverse incidents or claims.
• Business Scaling: Consistent, internationally accepted standards reduce obstacles when scaling production or entering new markets.

Compliance Considerations

• Documentation: Meticulous records of risk assessments, test results, and evaluations are required for audits and regulatory submissions.
• Ongoing Monitoring: As device designs, materials, or processes change, repeat assessments may be necessary to confirm ongoing safety.
• Harmonization: These standards complement broader quality management systems like ISO 13485 and are referenced in the MDR and FDA regulations.

Benefits of Adopting These Standards

• Enhanced Productivity: Streamlined testing and risk assessment processes accelerate R&D cycles
• Greater Security: Avoidance of safety-related adverse events or recalls
• Regulatory Readiness: Smooth pathway to market and adaptability to future regulatory changes
• Brand Value: Demonstrates leadership in responsible innovation

Risks of Non-Compliance

• Regulatory non-approval or market withdrawal
• Legal action from adverse patient events
• Increased costs due to re-testing or product redesign

Implementation Guidance

For health care businesses and device manufacturers, the journey to biological compliance can seem complex. Here are actionable tips to ease the path:

Common Implementation Approaches

1. Early Risk Assessment: Integrate biological evaluation from the initial design phase, not as an afterthought.
2. Material Selection: Choose biocompatible materials and collaborate with trusted suppliers whose ingredients have established safety profiles.
3. Test Strategy: Use in vitro models where possible to reduce costs and accelerate testing, but don’t skip crucial in vivo studies where necessary.
4. Documentation: Maintain organized records of every step—testing, data analysis, interpretation, and risk decisions.
5. Team Training: Invest in ongoing regulatory training for R&D, quality, and production teams.
6. Leverage Accredited Laboratories: Engage with certified testing labs experienced in the specific EN ISO 10993 requirements.
7. Be Proactive with Change Management: Re-assess and document safety whenever there are changes in materials, processes, or suppliers.

Best Practices for Adopting These Standards

• Build cross-functional teams including regulatory, R&D, and QA for holistic compliance
• Map device components and intended uses to relevant biologic tests early
• Regularly review updates to the ISO 10993 series and associated references
• Engage with standardization bodies and industry associations for guidance and updates
• Use official checklists and evaluation templates where available

Resources for Organizations

• Access standards documents directly from iTeh Standards or other accredited providers
• Attend industry workshops and online seminars focused on regulatory science and biological evaluation
• Utilize pre-market and post-market surveillance data to inform future product improvements

Conclusion / Next Steps

The world of medical devices moves fast, and the expectations for safety and efficacy are higher than ever. The EN ISO 10993 series, especially Parts 1, 10, 17, and 23, pave the way for a scientifically rigorous, globally harmonized approach to biological evaluation. By integrating these standards into product development and risk management systems, organizations not only meet regulatory requirements—they also create competitive advantage, safeguard users, and build trust.

Key takeaways:

• Biological evaluation standards are vital for safety, regulatory approval, and business success
• Consistent, early application boosts productivity and reduces costly surprises
• The four standards work together to cover a spectrum of biological risks—from irritation and sensitization, to comprehensive toxicological assessment

Recommendations:

• Review and align your organization's testing and compliance processes with the latest standards
• Invest in training, resources, and partnerships with accredited labs
• Stay proactive by monitoring ongoing regulatory and scientific updates

Ready to learn more or implement these standards in your organization? Explore the full standards for detailed procedures, testing protocols, and evidence requirements directly via the links below.

https://standards.iteh.ai/catalog/standards/cen/ce610ef5-e15d-41a9-b53b-87d5cef15ed7/en-iso-10993-10-2023

https://standards.iteh.ai/catalog/standards/cen/763af65d-2b0f-4723-b012-0b88e93fb8f0/en-iso-10993-1-2025

https://standards.iteh.ai/catalog/standards/cen/4f7f544e-9464-4bb1-b165-b5fa704d9cf4/en-iso-10993-17-2023

https://standards.iteh.ai/catalog/standards/cen/f201ba84-b586-47df-952e-b001a06b7346/en-iso-10993-23-2021